Welcome to our dedicated page for Indivior SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior’s filings rarely start with simple numbers—they dive straight into opioid-treatment revenues, clinical-trial minutiae, and litigation updates that can sway valuations overnight. Finding the paragraph that explains patent expiry or the table that breaks out Suboxone sales often means scrolling through hundreds of pages. Stock Titan condenses those complexities into clear takeaways, so you can grasp material events without forensic reading.
Need the latest Indivior quarterly earnings report 10-Q filing or its blockbuster annual report 10-K simplified? They’re here, updated from EDGAR in real time and paired with AI text that translates accounting language into plain English. Our engine pinpoints opioid settlement provisions, breaks down regional sales trends, and flags any Indivior 8-K material events explained within minutes of release. You’ll also find Indivior insider trading Form 4 transactions—each alert showing executive stock movements, with context from past patterns.
Curious about governance? The Indivior proxy statement executive compensation is parsed to show pay structures and performance metrics, while Indivior Form 4 insider transactions real-time dashboards highlight buying or selling before FDA milestones. Add in side-by-side comparisons, keyword search, and downloadable tables, and you have the tools to perform fast Indivior earnings report filing analysis. Whether you’re understanding Indivior SEC documents with AI for the first time or refining an existing model, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-1, and more—complete, searchable, and explained simply.
Indivior PLC (INDV) submitted a Form 144 reporting a proposed sale of Class A common stock. The notice lists 52,320 shares to be sold through J.P. Morgan Securities LLC with an aggregate market value of $1,278,178 and an approximate sale date of 08/28/2025 on the NYSE. The filing shows these shares were acquired by vesting of restricted stock units: 243,282 shares vested on 03/09/2025 and 9,974 shares vested on 03/16/2025, both through equity compensation from Indivior PLC. The filer reports 124,769,536 shares outstanding and indicates there were no securities sold in the past three months by the selling person. The form includes the standard seller representation regarding absence of undisclosed material adverse information.
Indivior PLC announced a three-phase operational plan—the Indivior Action Agenda—focused on generating momentum through 2025 by growing SUBLOCADE in the U.S., simplifying the organization, and accelerating long-acting injectable penetration and SUBLOCADE net revenue thereafter. On August 26, 2025 the company began Phase 1 initiatives that include headcount reductions, real estate consolidations, and consulting, legal, and tax planning. Indivior estimates $39–$50 million of pre-tax restructuring charges (about $27–$35 million cash) to be recognized in Q3 and Q4 2025 and says it will exclude these charges from non-GAAP measures. The company is also exploring strategic alternatives for OPVEE and its non-U.S. business; further one-time costs and savings could result. Estimates are subject to change based on assumptions and execution.
Indivior PLC announced it entered into a new U.S.-style Employment Agreement and a Confidentiality, Proprietary Rights and Non-Competition Agreement with its Chief Financial Officer, Ryan Preblick, replacing his prior 2020 agreement. The company states there were no changes to his compensation, responsibilities, or title. The agreement specifies an annual base salary of $558,819, an annual cash bonus opportunity targeted at 60% of base salary (with a maximum opportunity of 120%), and potential long-term incentive awards with a grant-date value anticipated at 400% of base salary, subject to the Compensation Committee's discretion. The full agreements are filed as Exhibit 10.1 and Exhibit 10.2 and are incorporated by reference.
The filing reports that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC jointly beneficially own 9,789,169 ordinary shares of Indivior PLC, representing approximately 7.8% of the class. The statement shows shared voting power of 9,789,144 shares and shared dispositive power of 9,789,169 shares, with no sole voting or sole dispositive power reported.
Exhibits identify the GS Group as a parent holding company and Goldman Sachs & Co. LLC as a broker-dealer and registered investment adviser. The filing includes a joint filing agreement and a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The statement provides ownership disclosure but does not disclose acquisition terms or strategic plans.
Q2 2025 snapshot: Net revenue rose 1% YoY to $302 m as SUBLOCADE sales grew 9% to $209 m, offsetting softer U.S. sublingual products. Gross margin expanded to 83% (74% last year) after prior-year PERSERIS exit costs rolled off. Operating income swung to $72 m from a $(118) m loss and diluted EPS reached $0.14 versus $(0.72). For the first half, revenue slipped 3% to $568 m but EPS improved to $0.52.
Cash & leverage: Operating cash flow jumped to $233 m, aided by delayed rebate payments, taking cash to $510 m and creating net cash of roughly $184 m against $326 m total debt. Capital-expenditure guidance remains $50-70 m for FY25, mainly for SUBLOCADE capacity.
Legal & tax items: Antitrust liabilities are down to an NPV of $20 m, and a $79 m provision covers opioid-MDL settlement offers. New dental-injury MDL (≈21,000 plaintiffs) and U.K. shareholder suits introduce fresh uncertainty. A £33 m HMRC reserve pushed the effective tax rate to 71%.
Strategic moves: LSE delisting completed; the company joins the Russell 2000/3000 and will lose foreign-private-issuer status in 2026. Manufacturing footprint is being consolidated; a Curia supply contract ends January 2026 without material penalties.
Management outlook: Guidance implies gross margin in the low-to-mid-80% range, SG&A/R&D below 2024, and continued double-digit SUBLOCADE growth sufficient to offset mature-product erosion. Management does not expect material impact from new U.S. tax legislation.
FAQ
What is the current stock price of Indivior (INDV)?
What is the market cap of Indivior (INDV)?
